
 <p style="text-align: center;"><b>Oregon Health &amp; Science University Hospital and Clinics Provider's Orders</b></p> <p style="font-size: small;">PO9031</p>  <p style="text-align: center;"><b>ADULT AMBULATORY INFUSION ORDER Ibandronate (BONIVA) Injection</b> Page 1 of 3</p>	<p>ACCOUNT NO. _____</p> <p>MED. REC. NO. _____</p> <p>NAME _____</p> <p>BIRTHDATE _____</p> <p style="text-align: right; font-size: x-small;"><i>Patient Identification</i></p>
<b>ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE.</b>	

Weight: \_\_\_\_\_ kg      Height: \_\_\_\_\_ cm

Allergies: \_\_\_\_\_

Diagnosis Code: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_      Patient to follow up with provider on date: \_\_\_\_\_

**\*\*This plan will expire after 365 days at which time a new order will need to be placed\*\***

**GUIDELINES FOR ORDERING**

1. Send **FACE SHEET and H&P or most recent chart note.**
2. Confirm patient has had recent oral/dental evaluation prior to initiating therapy.
3. All patients should be prescribed daily calcium and Vitamin D supplementation.
4. Discuss risk versus benefit regarding osteonecrosis of the jaw and hip fracture prior to treatment.
5. A complete metabolic panel must be obtained within 28 days prior to starting treatment.
6. **Must complete and answer the following question:**  
 Osteonecrosis of the jaw (ONJ) has been reported in patients receiving this medication. Risk factors include higher doses, duration of therapy greater than 2 years, cancer diagnosis, concurrent immunosuppression, poor oral hygiene, periodontal disease, ill-fitting dentures, and invasive dental procedures (among others). Provider attests that patient has had a dental evaluation or has no contraindications to therapy related to dental issues prior to initiating therapy.  
**Osteonecrosis of the jaw (ONJ) risk reviewed prior to initiation of therapy? \_\_\_\_ (Yes/No)**

**LABS:**

CMP, routine, ONCE, every visit

**NURSING ORDERS:**

1. TREATMENT PARAMETER #1 – When labs are ordered:
  - a. If serum calcium is greater than or equal to 8.4 mg/dL: OK to proceed with treatment.
  - b. If serum calcium less than 8.4 mg/dL AND albumin is less than 4.35 mg/dL: Calculate corrected calcium: Hold treatment and notify provider if corrected calcium is less than 8.4 mg/dL.
  - c. If serum calcium less than 8.4 mg/dL AND albumin is greater than or equal to 4.35 mg/dL: Hold treatment and notify provider.
2. TREATMENT PARAMETER #2 - Assess for new or unusual thigh, hip, groin, or jaw pain. Hold treatment and Contact provider if positive findings.  
 Invasive dental work includes dentoalveolar procedures such as tooth extraction, root canal, or placement of dental implants. Hold treatment and notify provider if the following has not been discussed with the ordering provider:
  - a. If patient is anticipating invasive dental work in the next 3 months
  - b. Has received invasive dental work in the last 8 week
  - c. Has a new diagnosis of severe periodontal disease
3. Hold treatment and notify provider for estimated Creatinine Clearance less than 30 mL/min.
4. Remind patient to take at least 500 mg elemental calcium twice daily and 400 IU Vitamin D daily.



Oregon Health & Science University  
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER  
**Ibandronate (BONIVA) Injection**  
Page 2 of 3

ACCOUNT NO.  
MED. REC. NO.  
NAME  
BIRTHDATE

*Patient Identification*

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.**

**MEDICATIONS:**

**ibandronate (BONIVA) 3 mg**, intravenous bolus, over 15 to 30 seconds, every 12 weeks for 4 treatments

**HYPERSENSITIVITY MEDICATIONS:**

1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.5 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

**By signing below, I represent the following:**

I am responsible for the care of the patient (*who is identified at the top of this form*);

I hold an active, unrestricted license to practice medicine in:  Oregon  \_\_\_\_\_ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

**My physician license Number is # \_\_\_\_\_ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION);** and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: \_\_\_\_\_ Date/Time: \_\_\_\_\_  
Printed Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_



Oregon Health & Science University  
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER  
**Ibandronate (BONIVA) Injection**  
Page 3 of 3

ACCOUNT NO.  
MED. REC. NO.  
NAME  
BIRTHDATE

*Patient Identification*

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE.**

***Please check the appropriate box for the patient's preferred clinic location:***

**Hillsboro Medical Center**

Infusion Services  
364 SE 8th Ave, Medical Plaza Suite 108B  
Hillsboro, OR 97123  
Phone number: (503) 681-4124  
Fax number: (503) 681-4120

**Adventist Health Portland**

Infusion Services  
10123 SE Market St  
Portland, OR 97216  
Phone number: (503) 261-6631  
Fax number: (503) 261-6756

**Mid-Columbia Medical Center**

Celilo Cancer Center  
1800 E 19th St  
The Dalles, OR 97058  
Phone number: (541) 296-7585  
Fax number: (541) 296-7610